Taste disorders and alopecia in myasthenia gravis

BMC Neurology

Table 2 Clinical features between MG patients with and without alopecia

	Alopecia group (n = 138, 8.2%)	Non-alopecia group (n = 1550, 91.8%)	P value
Female ratio	67.4% (93/138)	59.7% (924/1547)	0.0845
Age at MG onset, y	45.5 ± 17.2	48.3 ± 18.6	0.1078
Disease duration of MG, y	13.0 ± 10.5	12.0 ± 11.2	0.0565
Worst quantitative MG score	13.8 ± 7.4	12.6 ± 13.8	0.1061
History of bulbar palsy	59.4% (82/138)	50.3% (770/1531)	0.0412
History of crisis	8.0% (11/138)	8.4% (129/1529)	1.0000
MM or better status, current status	60.9% (84/138)	57.2% (886/1550)	0.4197
Refractory MG	23.5% (32/136)	20.9% (312/1494)	0.5099
MG subtype			0.0428
Ocular MG	15.9% (22/138)	22.1% (340/1540)	0.1050
EOMG	23.9% (33/138)	21.0% (323/1540)	0.4466
LOMG	16.7% (23/138)	20.8% (320/1540)	0.2722
TAMG	32.6% (45/138)	21.8% (337/1540)	0.0057
MuSKMG	1.4% (2/138)	3.1% (47/1540)	0.4273
SNMG	9.4% (13/138)	11.2% (173/1540)	0.5742
Alopecia
Onset after MG onset	36.8% (49/133)	-	-
Response to MG treatments	44.3% (47/106)	-	-
Onset after thymectomy	35.3% (24/68)	-	-

Values are presented as the mean ± standard deviation unless otherwise indicated
MG, myasthenia gravis; EOMG, early-onset MG; LOMG, late-onset MG; TAMG, thymoma-associated MG; MuSKMG, MuSK antibody-positive MG; SNMG, seronegative MG; MM, minimal manifestations; MM, minimal manifestations

ISSN: 1471-2377